Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for […]
Follow Us
-
+1 700 888 1234
-
Effingerstrasse 40 3008 Bern Switzerland
+1 700 888 1234
Effingerstrasse 40 3008 Bern Switzerland
Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for […]
We’re delighted to welcome five new member organisations to our growing Lung Cancer Europe (LuCE) network. These organisations and their […]
Bristol Myers Squibb has released a new Press Release announcing that the European Medicines Agency (EMA) has validated the marketing authorization application for repotrectinib. Repotrectinib […]
Financial impact of lung cancer: A European perspective High risk of financial vulnerability after diagnosis: The majority of people impacted […]
November 14th – 15th in Amsterdam We are delighted to announce that Lung Cancer Europe (LuCE) is participating in a two-day meeting […]
LuCE present at the ESMO Congress 2023 October 20th-24th in Madrid, Spain Our president Anne-Marie Baird had an active participation […]
consectetur adipisicing elit, sed do eiusmod tempor incididunt laboret dolore magna aliqua. Ut enim minim veniam quis nostrud exercitation ullamco laboris.
